Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... Oregon , July 29, 2014 ... "Global surgical equipment market (types, applications and geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... to reach $12.1 billion by 2020 registering a CAGR ... to the breakthrough achieved by the electro surgical devices ...
    (Date:7/29/2014)... Hershey, PA & Rockville, MD (PRWEB) July 29, ... Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in ... the financial services firm Newport Coast Securities, Inc. ... , ITI is commercializing LAMP-vax technology, a breakthrough ... $25B+ vaccines and immunotherapy market. The company exclusively ...
    (Date:7/29/2014)... Hill, South Carolina (PRWEB) July 29, 2014 ... with teams of people where cell phone masts or other ... iPhones up to 100 feet away without the need for ... to target longer ranges. , The new app has launched ... of US homes are at very high risk of being ...
    (Date:7/29/2014)... 29, 2014 The first product launch ... generation approach to robotics. What sets Droidles completely apart ... technology that allows them to communicate, share code with ... the internet. , “The invention is the system,” said ... Droidles a life of their own, both physically and ...
    Breaking Biology Technology:Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2
    ... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
    ... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
    ... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
    Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
    (Date:7/29/2014)... affects 1 in 100,000 people characterized by a loss ... remains unknown, a new study by a team of researchers ... Germany and other European institutions confirms for the first time ... 6 July in Nature Genetics , is an important ... a sphincter in the lower esophagus opens, allowing food to ...
    (Date:7/29/2014)... UC San Francisco is the first to show that ... accelerate cellular aging, these negative effects may be reduced ... , "The study participants who exercised, slept well ... ones who didn,t maintain healthy lifestyles, even when they ... Puterman, PhD, assistant professor in the department of psychiatry ...
    (Date:7/28/2014)... discovery of two additional coral communities showing signs of damage ... of the 2010 spill in the Gulf of Mexico. The ... professor of biology at Penn State University. A paper describing ... in the Gulf of Mexico will be published during the ... of the journal Proceedings of the National Academy of ...
    Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
    ... it may be more lyrical than useful when discussing ... of the Sackler Institute of Comparative Genomics at the ... the University of Colorado at Boulder. The team used ... the populations of small mammals living on mountaintops in ...
    ... on a nano scale how can you see what you ... Biological Sciences research Council (BBSRC) fellow has made a significant ... With new research published today (13 August) in ... School of Pharmacy (University of London) and the University of ...
    ... also available in German . Halle/Saale, ... plant species could lose parts of its current range, ... Environmental Research (UFZ), the Potsdam Institute for Climate Impact ... Species distributions will be rearranged as a result of ...
    Cached Biology News:Sky islands: metaphor or misnomer? 2Scientists overcome nanotech hurdle 2Scientists overcome nanotech hurdle 3Climate change threatens 1 in 5 plant species 2
    Prepared in distilled water....
    ... RiboGreen RNA Quantitation Kit is one ... for the quantitation of RNA in ... 1000-fold more sensitive than absorbance measurements. ... be detected with fluorescence microplate readers ...
    Request Info...
    Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
    Biology Products: